MOUNTAIN VIEW, Calif., June 17, 2011 /PRNewswire/ — VIVUS,
Inc. (Nasdaq:
VVUS) today announced that the positive results from REVIVE-RP
(TA-303), a phase 3 clinical trial evaluating the safety and
efficacy of the investigational drug avanafil for the treatment of
erectile dysfunction (ED),will be presented this afternoon at the
2011 Cancer Survivorship and Sexual Health Symposium in Washington
D.C.  The meeting is jointly sponsored by the International
Society for Sexual Medicine (ISSM) and the Sexual Medicine Society
of North America (SMSNA).  John Mulhall, M.D., Director of the
Male Sexual & Reproductive Medicine Program at the Memorial
Sloan Kettering Cancer Center in New York, will present the results
during the peer-reviewed, moderated poster session.  

Avanafil met all primary endpoints by demonstrating improvements
from baseline in erectile function as measured by the Sexual
Encounter Profile (both SEP 2 and SEP 3) and improvement in the
erectile function domain of International Index of Erectile
Function (IIEF).  The study also indicated a favorable safety
profile and successful intercourse (as measured by SEP 3) was
observed as early as 15 minutes after dosing, without any
restrictions on food or alcohol.

“Patients who have undergone a radical prostatectomy (RP) often
have severe erectile dysfunction.  Despite advancements in
surgery, it can take several months or years to normalize
erections.  RP patients are difficult to treat but the
positive results of avanafil in these patients suggest that, if
approved, avanafil could be an attractive treatment option for
these patients,” commented Dr. Mulhall.  “I am pleased to be
presenting these positive results with the health professionals
attending the Cancer Survivorship Meeting.  The safety and
efficacy demonstrated in this trial may offer hope to patients
who

‘/>”/>

SOURCE